Post a Comment Print Share on Facebook
Featured Feijóo Japón Educación Carles Puigdemont Pedro Sánchez

STATEMENT: IRBM will reveal the strong antitumor efficacy of new preclinical agents in AACR

(Information sent by the signatory company).

- 1 reads.

STATEMENT: IRBM will reveal the strong antitumor efficacy of new preclinical agents in AACR

(Information sent by the signatory company)

-IRBM to reveal strong antitumor efficacy of new preclinical agents against aggressive brain tumors and acute lymphoblastic leukemia in AACR

ROME, April 4, 2024 /PRNewswire/ -- IRBM, a leader in the field of drug discovery, announced today that it will disclose new data on two of its most promising internal assets at the upcoming annual meeting of the American Research Association Cancer Center (AACR) that will take place in San Diego from April 5 to 10. The data will reveal insights into new compounds developed to address critical unmet needs in cancer treatment.

Asset Highlights:

Carlo Toniatti, MD, PhD, Scientific Director of IRBM, expressed his excitement about the upcoming presentations: "The AACR meeting presents a unique opportunity for IRBM to share our latest advances in cancer research with the global scientific community. Our work in CRLF2/TLSPR targeting ADC and the CNS-penetrating small molecule inhibitor SHP2 exemplifies our relentless pursuit of novel therapeutic strategies that can make a significant difference in the lives of patients battling cancer. These developments reflect our deep scientific and innovative spirit, which underlines IRBM's role as a pioneer in the integrated drug discovery industry."

The two assets, which have advanced through the discovery phase within the public-private environment of the National Center for Detection and Collection of Chemical Compounds (CNCCS), are a testament to IRBM's integrated research capabilities, its commitment to advancing science to improve lives, and its search for new and better treatments for cancer.

Details of the poster presentations are listed below.

CNS-penetrating SHP2 inhibitor:

Session category: Experimental and molecular therapeutics

Session title: Kinase and phosphatase 2 inhibitors

Session date and time: Monday, April 8, 2024, 9:00 AM -12:30 PM

Lugar: Poster Section 25

Poster number: 24

Published summary number: 1975

Presenter: Francesca Puca, PhD. Principal Research Scientist

CRLF2/TLSPR objetivo a ADC:

Session category: Immunology

Session title: Antibody-drug conjugates

Session date and time: Monday, April 8, 2024, 1:30 PM - 5:00 PM

Lugar: Poster Section 2

Poster number: 13

Published abstract number: 2610

Presenter: Claudia Dall'Armi, PhD. Senior Research Investigator

About IRBM

IRBM is a scientific contract research organization (CRO) that is at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team advancements and improve efficiency from concept to candidate.

With a track record of contributing to four approved medicines and its own internal portfolio of oncology and other therapeutic assets, IRBM is driven by deep collaborations and decades of experience from leading global institutions. Its comprehensive in-house capabilities help partners achieve key milestones and move toward clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotechnology fields.


The National Collection of Chemical Compounds and Screening Center (CNCCS) is a public-private consortium created in 2010 by IRBM in collaboration with the Italian National Research Council (CNR) and the Italian National Institute of Health (ISS). It acts as a "leading factory", identifying compounds that act on innovative biological targets, as well as being a center for translational research in the areas of rare, neglected and poverty-related diseases.



View original content: